000145740 001__ 145740
000145740 005__ 20200925154157.0
000145740 037__ $$aDZNE-2020-01025
000145740 041__ $$aEnglish
000145740 1001_ $$0P:(DE-2719)2811989$$aDansokho, Dialy Cira$$b0$$eFirst author$$udzne
000145740 1112_ $$a47th Annual Meeting of the German Society for Immunology$$cErlangen$$d2017-09-12 - 2017-09-15$$wGermany
000145740 245__ $$aGeneration and characterization of patient-derived microglia-like cells for studying neuroinflammation in Alzheimer"s disease
000145740 260__ $$c2017
000145740 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1598434601_4498
000145740 3367_ $$033$$2EndNote$$aConference Paper
000145740 3367_ $$2BibTeX$$aINPROCEEDINGS
000145740 3367_ $$2DRIVER$$aconferenceObject
000145740 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000145740 3367_ $$2ORCID$$aOTHER
000145740 520__ $$aAlzheimer's disease (AD), the most common neurodegenerative disease, is characterized by extracellular deposits of amyloid peptides (Aβ), within senile plaques, and intracellular aggregation of hyperphosphorylated Tau protein causing neurofibrillary tangles (NFTs). AD is also defined by an extensive neuronal loss and chronic neuroinflammation mediated by microglial cells and astrocytes surrounding the lesions. Numerous preclinical and clinical studies have pointed out the strong contribution of neuroinflammation, in particular microglial responses, in the progression of AD. Therefore, deciphering cellular and molecular mechanisms underlying these neuroinflammatory processes may pave the way to the identification of new targets and biomarkers of AD. The generation of patient neural cells using induced pluripotent stem cell (iPSC) technology has helped to overcome the lack of success in modeling familial and sporadic AD. To identify new pathways involved in Alzheimer"s disease, we have set up, in our laboratory, a method to generate microglial cells using patient derived monocytes and iPSCs. The generated microglia-like cells have been then characterized for their phenotypes and functions regarding the genetic background and upon various stimulatory conditions.
000145740 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000145740 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b1$$eLast author$$udzne
000145740 8564_ $$uhttps://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.201770300
000145740 909CO $$ooai:pub.dzne.de:145740$$pVDB
000145740 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811989$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000145740 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000008$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000145740 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000145740 9141_ $$y2017
000145740 9201_ $$0I:(DE-2719)1011303$$kAG Heneka2$$lNeuroinflammation, Biomarker$$x0
000145740 980__ $$aabstract
000145740 980__ $$aVDB
000145740 980__ $$aI:(DE-2719)1011303
000145740 980__ $$aUNRESTRICTED